Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.

Although tumor volume and new lesions (NLs) have been investigated previously as measures of response, the clinical impact of changes in tumor uptake on prostate-specific membrane antigen (PSMA) PET remains largely unknown. This multicenter retrospective study investigated the clinical impact of changes in tumor uptake and volume on PSMA PET during [Lu]Lu-PSMA in metastatic castration-resistant prostate cancer (mCRPC). The primary outcomes were the associations of changes in SUV (ΔSUV) and SUV (ΔSUV), changes in total tumor volume (ΔTTV), and occurrence of NLs with prostate-specific antigen (PSA) progression-free survival (PSA-PFS) and overall survival (OS). The study included patients with mCRPC who received [Lu]Lu-PSMA between 2014 and 2019. PSMA PET/CT was performed at baseline and after 2 cycles of therapy. Whole-body analyses (SUV, SUV, TTV, and NLs) were performed and calculated using qPSMA software. In total, 124 patients with mCRPC (median age, 73 y; interquartile range, 67-76 y) were included in the study. Whole-body ΔTTV and the occurrence of NLs were significantly associated with shorter PSA-PFS (hazard ratio [HR], 5.7; 95% CI, 3.59-9.06; and HR, 1.6; 95% CI, 1.4-1.8; < 0.0001) and with OS (HR, 2.3; 95% CI, 1.61-3.43; and HR, 1.3; 95% CI, 1.1-1.4; < 0.001). Patient-based analysis showed that ΔSUV and ΔSUV were not associated with outcome (HR, 1.00; 95% CI, 0.99-1.00; = 0.30; and HR, 0.90; 95% CI, 0.99-1.00; = 0.11). Region-based analysis found that only ΔSUV in visceral lesions was significantly associated with PSA-PFS ( = 0.007) but not with OS. Only ΔTTV and the occurrence of NLs provided significant prognostic value and should be considered when evaluating treatment response to [Lu]Lu-PSMA therapy.